Gaps In using bronchodilators, inhaled corticosteroids and influenza vaccine among 23 high- and low-income sitesReport as inadecuate




Gaps In using bronchodilators, inhaled corticosteroids and influenza vaccine among 23 high- and low-income sites - Download this document for free, or read online. Document in PDF available to download.

Reference: Gnatiuc, L, Buist, AS, Kato, BS et al., (2015). Gaps In using bronchodilators, inhaled corticosteroids and influenza vaccine among 23 high- and low-income sites. International Journal of Tuberculosis and Lung Disease, 19 (1), 21-30.Citable link to this page:

 

Gaps In using bronchodilators, inhaled corticosteroids and influenza vaccine among 23 high- and low-income sites

Abstract: BackgroundIncreasing access to essential respiratory medicines and influenza vaccination has been a priority for over three decades. Their use remains low in low- and middle-income countries (LMICs), where little is known about factors influencing use, or about the use of influenza vaccination for preventing respiratory exacerbations.MethodsWe estimated rates of regular use of bronchodilators, inhaled corticosteroids and influenza vaccine, and predictors for use among 19 000 adults in 23 high-income countries (HICs) and LMIC sites. ResultsBronchodilators, inhaled corticosteroids and influenza vaccine were used significantly more in HICs than in LMICs, after adjusting for similar clinical needs. Although they are used more commonly by people with symptomatic or severe respiratory disease, the gap between HICs and LMICs is not explained by the prevalence of chronic obstructive pulmonary disease or doctor-diagnosed asthma. Site-specific factors are likely to influence use differently. The gross national income per capita for the country is a strong predictor for use of these treatments, suggesting that economics influence under-treatment.ConclusionWe still need a better understanding of determinants for the low use of essential respiratory medicines and influenza vaccine in low-income settings. Identifying and addressing these more systematically could improve the access and use of effective treatments.



Author: Gnatiuc, L - institutionUniversity of Oxford Oxford, MSD, Nuffield Department of Population Health, Clinical Trial Service Unit -

Source: https://ora.ox.ac.uk/objects/uuid:c15b28ed-a74f-44d2-8d1e-984b2ec457cf



DOWNLOAD PDF




Related documents